Dana E. Rathkopf
About
Dana E. Rathkopf is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Dana E. Rathkopf has authored 203 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Pulmonary and Respiratory Medicine, 101 papers in Radiology, Nuclear Medicine and Imaging and 96 papers in Oncology. Recurrent topics in Dana E. Rathkopf's work include Prostate Cancer Treatment and Research (179 papers), Radiopharmaceutical Chemistry and Applications (99 papers) and Cancer Treatment and Pharmacology (34 papers). Dana E. Rathkopf is often cited by papers focused on Prostate Cancer Treatment and Research (179 papers), Radiopharmaceutical Chemistry and Applications (99 papers) and Cancer Treatment and Pharmacology (34 papers). Dana E. Rathkopf collaborates with scholars based in United States, United Kingdom and France. Dana E. Rathkopf's co-authors include Howard I. Scher, Philip W. Kantoff, Min Yuen Teo, Michael J. Morris, Daniel C. Danila, Steven M. Larson, Celestia S. Higano, Joshi J. Alumkal, Charles J. Ryan and Martin Fleisher and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Dana E. Rathkopf
191 papers receiving 5.2k citations
Hit Papers
Peers
Dana E. Rathkopf
Mohammad Hirmand United States
Joshi J. Alumkal United States
Mary Ellen Taplin United States
Matthew M. Cooney United States
Bryan Selby United States
Simon Chowdhury United Kingdom
J Horti Hungary
Eleni Efstathiou United States
Glenn Liu United States
William R. Berry United States
Citations per year, relative to Dana E. Rathkopf Dana E. Rathkopf (= 1×)
peers
Mohammad Hirmand
Countries citing papers authored by Dana E. Rathkopf
Since
Specialization
Citations
This map shows the geographic impact of Dana E. Rathkopf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana E. Rathkopf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana E. Rathkopf more than expected).
Fields of papers citing papers by Dana E. Rathkopf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dana E. Rathkopf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana E. Rathkopf. The network helps show where Dana E. Rathkopf may publish in the future.
Co-authorship network of co-authors of Dana E. Rathkopf
This figure shows the co-authorship network connecting the top 25 collaborators of Dana E. Rathkopf. A scholar is included among the top collaborators of Dana E. Rathkopf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana E. Rathkopf. Dana E. Rathkopf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Autio, Karen A., Deaglan Joseph McHugh, Dana E. Rathkopf, et al.. (2025). Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer. PubMed. 8(2). 172–176.
2.
Azad, Arun, Qiang Dong, Alicia K. Morgans, et al.. (2025). Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 43(5_suppl). 147–147.
3.
Rathkopf, Dana E., Guilhem Roubaud, Kim N., et al.. (2024). Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. European Urology. 88(4). 359–369.
4.
Lang, Joshua M., Susan F. Slovin, Jamie M. Sperger, et al.. (2024). 1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Annals of Oncology. 35. S993–S994.
5.
Hoffman, Richard M., Paul L. Nguyen, Dana E. Rathkopf, et al.. (2024). Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics. 120(2). S54–S54.
6.
Castro, Elena, Gerhardt Attard, Matthew R. Smith, et al.. (2023). LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. Annals of Oncology. 34. S1326–S1326.
7.
Nguyen, Paul L., Marisa Kollmeier, Dana E. Rathkopf, et al.. (2023). FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal of Radiation Oncology*Biology*Physics. 117(2). S81–S82.
8.
Halabi, Susan, Qian Yang, Bin Luo, et al.. (2023). External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 41(15). 2736–2746.
9.
Rencsok, Emily M., Konrad H. Stopsack, Daniel J. George, et al.. (2023). Abstract 6489: Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort. Cancer Research. 83(7_Supplement). 6489–6489.
10.
Attard, G., Shahneen Sandhu, Dana E. Rathkopf, et al.. (2023). 1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial. Annals of Oncology. 34. S976–S977.
11.
Wilson, Brooke E., Andrew J. Armstrong, Johann S. de Bono, et al.. (2022). Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer. 170. 296–304.
12.
Sarfaty, Michal, Darren R. Feldman, Michael J. Morris, et al.. (2021). Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clinical Genitourinary Cancer. 19(3). e178–e183.
13.
Münster, Pamela N., Monica Mita, Amit Mahipal, et al.. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. SHILAP Revista de lepidopterología.
14.
Graham, Laura, Kalyan Banda, Alba Torres, et al.. (2018). A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs. 36(3). 458–467.
15.
Rathkopf, Dana E., Emmanuel S. Antonarakis, Neal D. Shore, et al.. (2017). Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research. 23(14). 3544–3551.
16.
Bryce, Alan H., Joshi J. Alumkal, Andrew J. Armstrong, et al.. (2017). Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases. 20(2). 221–227.
17.
Morris, Michael J., Dana E. Rathkopf, William Novotny, et al.. (2016). Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(15). 3774–3781.
18.
Carles, Joan, Ian D. Davis, Johann S. de Bono, et al.. (2016). Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs). Annals of Oncology. 27. vi251–vi251.
19.
Attard, Gerhardt, Johann S. de Bono, Christopher J. Logothetis, et al.. (2015). Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research. 21(7). 1621–1627.
20.
Scher, Howard I., Tomasz M. Beer, Celestia S. Higano, et al.. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. The Lancet. 375(9724). 1437–1446.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by Joshi J. Alumkal Breakdown of academic impact, for papers by Mary Ellen Taplin Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Bryan Selby Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Glenn Liu Breakdown of academic impact, for papers by William R. Berry